|
Showing 1 - 1 of
1 matches in All Departments
The covalent conjugation of potent cytotoxic agents to monoclonal
antibodies, known as antibody-drug conjugates (ADCs) is a powerful
approach in the field of targeted treatment of cancer. Clearly,
both monoclonal antibody and cytotoxic payload are crucial elements
in determining the clinical value of an ADC and have receive ample
attention. However, the structural element connecting the two -the
chemical linker- also plays an essential role in mode-of-action,
efficacy, pharmacokinetics and safety profile of an ADC, but is
often underappreciated in considerations of ADC design. Chemical
Linkers in Antibody-Drug Conjugates aims to shine a detailed light
on the various key attributes of chemical linkers in ADCs, for
drug-to-antibody ratio, for stability, for release mechanism of
payload, for pharmacokinetics, for stability determination, and for
efficacy and safety. Ideal for postgraduate students and active
researchers in drug discovery and development, this book provides a
comprehensive description of linkers used in ADCs (clinical and
late preclinical), insight into key quality attributes of linkers
for ADCs, and aids the reader in understanding the role of linker
chemistry and designing new ADCs.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.